Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
about
Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor.Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression.Polo-like kinase-1 immunoreactivity is associated with metastases in cutaneous melanoma.PLK1 protects against sepsis-induced intestinal barrier dysfunction.
P2860
Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Small molecule inhibition of p ...... delay and regression in vivo.
@en
type
label
Small molecule inhibition of p ...... delay and regression in vivo.
@en
prefLabel
Small molecule inhibition of p ...... delay and regression in vivo.
@en
P2093
P2860
P1433
P1476
Small molecule inhibition of p ...... delay and regression in vivo.
@en
P2093
Brian D Cholewa
Mary A Ndiaye
Nihal Ahmad
Xiaoqi Liu
P2860
P304
P356
10.1016/J.CANLET.2016.10.025
P407
P577
2016-10-25T00:00:00Z